相关实验视频

Updated: Jul 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

涅拉提尼布用于治疗 HER2 阳性乳腺癌,这是一个被忽视的选择

Liting Guo¹, Weiwei Shao², Chenfei Zhou³

¹Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. gltonline@163.com.

Molecular medicine (Cambridge, Mass.)

|October 6, 2023

概括

涅拉替尼在治疗先进的HER2阳性乳腺癌 (BC) 中表现有前途,特别是在预防和控制大脑转移方面. 这种氨酸激酶抑制剂为BC患者提供了一种新的治疗策略,可以控制腹等副作用.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
医学科学医学科学医学科学

背景情况:

HER2阳性乳腺癌 (BC) 携带转移的高风险,特别是在大脑.
涅拉丁尼是一种氨酸激酶抑制剂,向HER1,HER2和HER4信号通路.
涅拉替尼在克服先前用HER2向疗法治疗的BC患者的耐药性方面表现出有效性.

研究的目的:

审查neratinib的药理概况,疗效,安全性和临床试验.
专注于内拉替尼在转移性乳腺癌 (MBC) 中的作用,其中包括中枢神经系统 (CNS).
讨论内拉替尼在HER2-阴性和HER2-突变乳腺癌以及耐药机制中的潜力.

主要方法:

对药理学数据,临床试验结果和neratinib的安全性概况的审查.
专注于涉及neratinib在BC.早期,辅助和转移的设置中的研究.
对内拉替尼在中枢神经系统转移中的疗效进行分析,并与现有治疗方法进行比较.

主要成果:

涅拉提尼布具有较高的抗癌活性,适用于长期辅助治疗HER2阳性早期BC.
在先进的HER2阳性BC中,单独或组合的内拉替尼显示出有效性,特别是在降低BC复发风险和中枢神经系统转移方面.
涅拉蒂尼布的疗效与以前的疗法相当或优于它,腹是最常见的不良反应,可用洛佩拉米德治疗.

结论:

涅拉替尼是治疗HER2阳性乳腺癌的一个有前途的治疗选择,包括脑转移病例.
该药物有效控制和预防大脑转移,为高级BC提供了有价值的策略.
进一步的研究和临床试验正在进行中,以探索neratinib在各种BC环境中的全部潜力.

关键词:

乳腺癌乳腺癌乳腺癌中央神经系统的转移.在HER2中,HER2是HER2.尼拉丁尼布 (Neratinib) 是一种有毒的药物.

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...